Avalo gains as Cantor initiates with bullish view on lead asset

[Wall Street sign in Lower Manhattan, NYC]
georgeclerk

Avalo Therapeutics (NASDAQ:AVTX [https://seekingalpha.com/symbol/AVTX]) traded higher in the premarket on Friday after Cantor Fitzgerald initiated its coverage with an Overweight recommendation in a thesis centered on the Maryland-based biotech’s lead asset, AVTX-009.

Analyst Prakhar Agrawal’s bullish view comes as Avalo (NASDAQ:AVTX [https://seekingalpha.com/symbol/AVTX]) targets a mid-2026 data release from its Phase 2 LOTUS trial for the interleukin-1β antibody in hidradenitis suppurativa, an inflammatory skin condition. [https://seekingalpha.com/pr/20192783-avalo-reports-second-quarter-2025-financial-results-and-recent-business-updates]

Citing a “strong validation” from AbbVie’s (ABBV [https://seekingalpha.com/symbol/ABBV]) competitive candidate lutikizumab, designed to target IL-1α and IL-1β, Agrawal says he is positive on the prospects for AVTX-009, which, according to him, has approximately $1B in adjusted peak sales potential.

The analyst noted “a very attractive risk/reward for AVTX into the Ph2 HS readout based on the implied probability of success (15-20% by our estimate) in the stock for HS, which seems very low to us based on the validation from lutikizumab.”

MORE ON AVALO THERAPEUTICS

* Seeking Alpha’s Quant Rating on Avalo Therapeutics [https://seekingalpha.com/symbol/AVTX/ratings/quant-ratings]
* Historical earnings data for Avalo Therapeutics [https://seekingalpha.com/symbol/AVTX/earnings]
* Financial information for Avalo Therapeutics [https://seekingalpha.com/symbol/AVTX/income-statement]